Disseminated mycobacterial infections after tumor necrosis factor inhibitor use, revealing inborn errors of immunity
- PMID: 37037391
- PMCID: PMC10339357
- DOI: 10.1016/j.ijid.2023.04.007
Disseminated mycobacterial infections after tumor necrosis factor inhibitor use, revealing inborn errors of immunity
Abstract
Tumor necrosis factor-a inhibitors can be associated with increased risk of infections, particularly reactivation of latent tuberculosis or nontuberculous mycobacterium (NTM). However, because disseminated NTM is rare, inborn errors of immunity should be considered. We present three patients with disseminated NTM after tumor necrosis factor-a inhibitor use who were found to have inborn errors of immunity.
Keywords: Immunodeficiency; Inborn errors of immunity; Infliximab; Mycobacteria; TNF inhibitor.
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no competing interests to declare.
Figures
References
-
- Roach DR, et al., TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol, 2002. 168(9): p. 4620–7. - PubMed
-
- Keane J, et al., Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 2001. 345(15): p. 1098–104. - PubMed
-
- Wallis RS, et al., Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis, 2004. 38(9): p. 1261–5. - PubMed
-
- Conrad A, et al., Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. J Clin Immunol, 2021. 41(1): p. 185–193. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
